MOLN

2.5255.25%
VJ

Vito J. Palombella

Independent Director

Dr. Vito J. Palombella, Ph.D., is Chief Scientific Officer at Triana Biomedicines, Inc. since September 2023. He serves as an Advisor at Atlas Venture Advisors, Inc. (formerly known as Atlas Venture L.P.). since 2017 and had been Chief Scientific Officer of Surface Oncology, Inc since January 2016 until 2023. Dr. Palombella serves as Director at Molecular Partners AG since April 29, 2020. Dr. Palombella served in a variety of roles at Infinity Pharmaceuticals, Inc. from January 2004 to January 2016 and serves as its Chief Scientific Officer. He was Director of Molecular Biology and Protein Chemistry at Syntonix Pharmaceuticals, Inc. (now Biogen Inc.) from October 2000 to January 2004 and Senior Director of Cell and Molecular Biology at Millennium Pharmaceuticals, Inc. (now Takeda Pharmaceutical Co. Ltd.) from December 1999 to October 2000, Senior Director of Cell and Molecular Biology at LeukoSite, Inc. from July 1999 to December 1999, and held a number of positions at ProScript, Inc. from September 1994 to July 1999. He served as the Chief Scientific Officer and Executive Vice President of Infinity Pharmaceuticals, Inc. from May 2010 to January 22, 2016. Dr. Palombella served as Vice President of Drug Discovery at Infinity Pharmaceuticals, Inc. from September 2006 to May 2010 and also served as its Vice President of Biology from January 2004 to September 2006. Dr. Palombella focused on improving and expanding Infinity Pharmaceuticals, Inc.'s core Fc receptor-mediated drug delivery technology (Transceptor). Before joining Syntonix, Dr. Palombella served as Senior Director of Cell and Molecular Biology at Millennium Pharmaceuticals, Inc. (now Takeda Pharmaceutical Co. Ltd.), which he joined through its acquisition of LeukoSite (where he held the same title) in 1999. Dr. Palombella held a number of positions at ProScript, Inc. (between 1994 and 1999). While at ProScript, LeukoSite and Millennium, Dr. Palombella was involved with the discovery and development of approved drug VELCADE®, a proteasome inhibitor for cancer therapy. He managed a number of additional cellular and molecular biology projects, including research into NF-kB regulation, which became part of Millennium's discovery research collaboration with Aventis. He serves as Member of Scientific Advisory Board at IFM Therapeutics, Inc. Dr. Palombella received a B.S. degree in Microbiology from Rutgers University and his M.S. and Ph.D. in Viral Oncology and Immunology at the New York University Medical Center. He was also a postdoctoral fellow at Harvard University.

Positions